Literature DB >> 12818688

Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitors.

Sabiha Alper1, Ozlem Temiz Arpaci, Esin Sener Aki, Ismail Yalçin.   

Abstract

The discovery of DNA topoisomerases has added a new dimension to the study of anticancer drugs. In the last years detailed investigation of bi- and ter-benzimidazole derivatives revealed that these compounds are a new class of topoisomerase I inhibitors that poisons mammalian topoisomerase I. In this context a survey about topoisomerase I poisoning activity and cytotoxicity of bi- and ter-benzimidazoles is given. Moreover some recent results about new derivatives, some structure-activity relationships and comparison of activity of various functional groups are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818688     DOI: 10.1016/S0014-827X(03)00042-9

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  3 in total

1.  Functionalization of carboxylated multiwall nanotubes with imidazole derivatives and their toxicity investigations.

Authors:  Javad Azizian; Hasan Tahermansouri; Esmaeil Biazar; Saeed Heidari; Davood Chobfrosh Khoei
Journal:  Int J Nanomedicine       Date:  2010-11-04

2.  3-[1-(3-Hy-droxy-benz-yl)-1H-benzimid-azol-2-yl]phenol dimethyl sulfoxide monosolvate.

Authors:  Magdalena Quezada-Miriel; Alcives Avila-Sorrosa; Juan Manuel German-Acacio; Reyna Reyes-Martínez; David Morales-Morales
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-09-29

3.  Conjugation of benzylvanillin and benzimidazole structure improves DNA binding with enhanced antileukemic properties.

Authors:  Zena A Al-Mudaris; Aman S A Majid; Dan Ji; Ban A Al-Mudarris; Shih-Hsun Chen; Po-Huang Liang; Hasnah Osman; Shah Kamal Khan Jamal Din; Amin M S Abdul Majid
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.